F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Wikipedia.
Hoffmann-La Roche | Date: 2017-04-19
Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain variable domain (numbering according to Kabat), at positions 55-83 in the light chain variable domain (numbering according to Kabat), at positions 145-174 in the first heavy chain constant domain (numbering according to EU index) and at positions 180- 97 in the first heavy chain constant domain (numbering according to EU index), b) determining the binding strength of each of the full length antibodies from the 10 plurality of antibodies to the human neonatal Fc receptor (FcRn), and c) selecting a full length antibody from the plurality of full length antibodies that has a different binding strength to the FcRn than the parent full length antibody.
Hoffmann-La Roche | Date: 2017-01-04
The present invention relates to compounds of formula I, wherein Y is N or C-R1; R1 is hydrogen or F; R1 is hydrogen, halogen or lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; or R2 forms together with R4 a 6 membered heterocyclic ring containing -CH2-CH2-O-CH2- or -CH2-CH2-NR-C(O)-; R is hydrogen, lower alkyl, phenyl or benzyl; R3 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; R4 is hydrogen, lower alkyl or lower alkoxyalkyl; R4 is hydrogen, lower alkyl, phenyl optionally substituted by halogen or lower alkoxy, or is cycloalkyl, or is pyridinyl optionally substituted by halogen, lower alkyl, lower alkoxy or =0, or is pyrimidinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is 1 -lower alkyl-pyridinyl, or is pyrazinyl, or is pyridazinyl optionally substituted by lower alkyl, lower alkoxy or =0, or is l-methylpyrrolo[2,3-b]pyridine-5-yl, or is 6-imidazo[l,2- b]pyridazin-6-yl; or R4 forms together with R4 a 4, 5 or 6 membered heterocyclic ring containing -(CH2)5-, -CH2-CH2-O-CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-O-CH2-CH2- or CH2-CH2-CH2-O-CH2; R5 and R5 are hydrogen or lower alkyl; or R4 forms together with R5 a saturated 5- membered ring containing -CH2-CH2-CH2-; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Parkinsons disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
Hoffmann-La Roche | Date: 2017-03-08
The invention is related to compounds, which are GlyTl inhibitors, for use in the treatment of hematological disorders, in particular for use in the treatment of sickle cell disease and thalassemia, or for the treatment of patients with iron overload syndromes, such as hereditary hemochromatosis.
Hoffmann-La Roche | Date: 2017-03-22
The disclosure relates to anti-HERI antigen binding proteins, e.g. anti-HERI antibodies, that bind to the beta-hairpin of HER1, methods for selecting these antigen binding proteins, their preparation and use as medicament.
Hoffmann-La Roche | Date: 2017-03-22
The disclosure relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
Hoffmann-La Roche, Hoffmann-La Roche and Dynamic Biosensors GmbH | Date: 2017-01-04
The present invention relates to a method of identifying a nucleotide at a defined position and determining the sequence of a target polynucleotide using an electro-switchable biosensor, as well as devices comprising an electro-switchable biosensor and uses thereof.
Hoffmann-La Roche and Hoffmann-La Roche | Date: 2017-04-12
The invention provides for a cartridge (300) for an automatic analyzer (1100), wherein the cartridge is operable for being spun around a rotational axis (102). The cartridge comprises: a fluid chamber (104) for receiving a fluid (307), an aliquoting chamber (108), a first duct (106) connecting the fluid chamber and the aliquoting chamber, a metering chamber (112) operable for causing fluid to fill the metering chamber using capillary action, a second duct (110) connecting the metering chamber with the aliquoting chamber, and a vent (128). The vent is connected to the metering chamber. The vent is nearer to the rotational axis than the metering chamber. The metering chamber has side walls (204) and a central region (206). The side walls taper away from the central region, wherein capillary action next to the side walls of the metering chamber is greater than in the central region of the metering chamber. The second duct comprises a duct entrance (114) in the aliquoting chamber. The second duct further comprises a duct exit (116) in the metering chamber wherein the duct exit is closer to the rotational axis than the duct entrance. The second duct is operable for causing fluid to flow to the metering chamber using capillary action. The cartridge further comprises a downstream fluidic element (122) connected to the metering chamber via a valve (121) and a fluidic structure (336) for processing a biological sample into the processed biological sample. The fluidic structure comprises a measurement structure (344, 1110) for enabling measurement of the processed biological sample, wherein the fluidic structure is configured for receiving the biological sample.
Hoffmann-La Roche and Hoffmann-La Roche | Date: 2017-03-29
Handheld analyte meters are provided that have a measurement module, a rechargeable battery and a charging control to select a maximum charging current to regulate self-heating during recharging that can interfere with analyte tests. Prior to beginning a charging session, the charging control selects the maximum charging current that does not change during the charging session based capacity of a charging source along with a first temperature measured near the battery that is compared with a first temperature range. By selecting the maximum charging current in this manner, the risk of the measurement module preventing a test under high lock-out conditions and the risk of the measurement module allowing a test when low lock-out conditions that are masked is reduced. Methods also are provided for using/operating such devices.
Hoffmann-La Roche and Hoffmann-La Roche | Date: 2017-02-08
The present invention relates to a method for cross-linking polypeptide molecules, comprising the step of combining a cross-linking agent and polypeptide molecules in solution under conditions suitable for a cross-linking reaction to occur and to a preparation comprising cross-linked polypeptide molecules obtainable by said method. The present invention further relates to cross-linked polypeptide molecules, wherein said polypeptide molecules are cross-linked by essentially unbranched cross-linking groups comprising at least 40 contiguous atoms. Moreover, the present invention relates to a test chemistry matrix comprising a redox cofactor, an agent capable of eliciting a change in at least one measurable property of an indicator reagent in the presence of redox equivalents, and an indicator reagent, wherein said chemistry matrix further comprises a preparation of cross-linked polypeptide molecules obtainable by the method according to the present invention and/or cross-linked polypeptide molecules according tothe present invention, as well as to a diagnostic test element comprising said test chemistry matrix. The present invention further relates to a preparation of cross-linked polypeptide molecules obtainable by the method according the present invention and/or cross-linked polypeptide molecules according to the present invention for use in the diagnosis of disease and for use in diagnosis of diabetes, as well as to a method for producing a test chemistry matrix.
De Wit J.,Catholic University of Leuven |
Ghosh A.,Roche Holding AG
Nature Reviews Neuroscience | Year: 2016
The molecular diversification of cell surface molecules has long been postulated to impart specific surface identities on neuronal cell types. The existence of unique cell surface identities would allow neurons to distinguish one another and connect with their appropriate target cells. Although progress has been made in identifying cell type-specific surface molecule repertoires and in characterizing their extracellular interactions, determining how this molecular diversity contributes to the precise wiring of neural circuitry has proven challenging. Here, we review the role of the cadherin, neurexin, immunoglobulin and leucine-rich repeat protein superfamilies in the specification of connectivity. The emerging evidence suggests that the concerted actions of these proteins may critically contribute to the assembly of neural circuits. © 2016 Macmillan Publishers Limited. All rights reserved.